Company Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.
The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 1989 |
| IPO Date | Feb 4, 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 314 |
| CEO | Dominick Colangelo |
Contact Details
Address: 64 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617 588 5555 |
| Website | vcel.com |
Stock Details
| Ticker Symbol | VCEL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000887359 |
| CUSIP Number | 92346J108 |
| ISIN Number | US92346J1088 |
| Employer ID | 94-3096597 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dominick Colangelo | Chief Executive Officer |
| Joseph Mara | Chief Financial Officer |
| Michael Halpin | Chief Operating Officer |
| Eric Burns | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 5, 2025 | 144 | Filing |
| Feb 5, 2025 | 144 | Filing |
| Jan 28, 2025 | 144 | Filing |
| Jan 14, 2025 | 8-K | Current Report |
| Dec 4, 2024 | 144 | Filing |
| Dec 2, 2024 | 144 | Filing |
| Nov 22, 2024 | 144 | Filing |
| Nov 14, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |